Introduction
Coagulation and cancer development
Coagulation factors | Effects |
---|---|
Tissue factor (TF) ↑ | Promoting angiogenesis by activation of MAPK[73] and protein C kinase C-dependent signaling[76]; TF-PAR2 selectively synergizes with PDGF-BB to enhance to metastasis in lymphnodes[78]. Promoting invasion and metastasis by the activation of P21Ras and P42/P44 MAPK pathway to inhibit apoptosis[14]; overexpressing growth factors and chemokines (i.e. IL-8)[13]. |
TF-VII-PAR2 ↑ | Promoting angiogenesis, invasion, and metastasis by clotting-independent mechanism[77] in presence of inflammatory cytokines |
Factor X ↑ | Forming complex with TF-VIIa to promote tumor angiogenesis and metastasis[14] |
Thrombin/PAR1 ↑ | Promoting angiogenesis by inhibiting EC migration to collagen type IV or to laminin[99]; upregulating VEGF expression[100]. Promoting invasion and metastasis depended on at least 6 mechanisms (text) |
Fibrinogen/fibrin ↑ | Stimulating angiogenesis; the fibrin gel matrix facilitating tumor metastasis; increasing plasma exudates to form ascites[129, 130, 132]. |
Factor XII/XI ↑ | Positive feedback on human kallikreins system |
Factor XIII ↑ | Form stable fibrin |
Regulatory proteins
| |
Heparin cofactor II ↑ | Produce chemoattractant peptide for MAs migration. |
Endothelial protein C receptor ↑ | Intensifying APC-PAR1 signal transduction [205] and contributing to antiapoptosis in tumor. |
Tissue factor pathway inhibitor ↓ | Loss of control of tumor growth and metastasis by activating Factor Xa and increasing Factor Xa-PAR2 signaling[81]. |
Tissue factor pathway inhibitor-2 ↓ | Loss of Inhibiting TF-VIIa complex and various protease but not Factor Xa; Loss of antiangiogenesis and antimetastasis. |
Factor XII and the kallikrein family (positive feedback loop)
hK family member | Location | Expression level and site | Clinical feature | Prognosis |
---|---|---|---|---|
hK4 | Tumor cells | Increased in EOC tissue | Predictive marker for paclitaxel resistance[22] | Unfavorable |
hK5 | Serum, ascites, and tumor extracts [23, 24] | Increased on tumor cells and in serum and ascites | Potential biomarker for diagnosis | Unfavorable |
hK6 | Tumor cell[26] and serum[25] | High in early-stage and low-grade tumor tissue and in EOC serum | Overexpression is an early phenomenon in the development of ECO; serum level could be used as a biomarker | Unfavorable |
hK7 | Tumor tissue[27] | High in late-stage EOC | A potential biomarker for diagnosis | Unfavorable |
hK8 | Tumor extract, serum, and ascites[29] | High in serum and ascites | High level is associated with good prognosis[28, 29] | Favorable |
hK9 | Tumor cells[30] | High in tumor tissue early-stage and optimal debulking patients | Associated with longer progression-free and overall survival times | Favorable |
hK10 | Serum[33] and tumor cells[31,32] | High in serum and on tumor cells | High serum level is associated with increased risk for relapse and death; a potential biomarker for diagnosis | Unfavorable |
hK11 | Serum, ascites[37], and tumor extract [34-36] | Increased in tumor samples | High level is an independent factor for favorable prognosis and is associated with long progression-free and overall survival times and with slower disease progression[34, 35]; however, high level is also associated with poor survival rate[36]. | Depends |
hK13 | Tumor tissue[38] | verexpressed in tumor tissue | Associated with longer progression-free and overall survival times | Favorable |
hK14 | Tumor cells[41] and serum[40] | Increased in tumor tissue and serum | Associated with longer progression-free and overall survival times; an independent prognostic factor | Favorable |
hK15 | Tumor extract[42] | Increased in tumor tissue | Associated with short progression-free and overall survival times; an independent prognostic factor | Unfavorable |
Factor XI
Tissue factor
TF and angiogenesis
TF and metastasis
Thrombin and thrombin receptor
Thrombin-PAR system and angiogenesis
Thrombin-PAR system in invasion and metastasis
Factor XIII and fibrin
Fibrin and angiogenesis
Regulatory proteins in the coagulation cascade
EPCR
The connection between coagulation and inflammation in the EOC peritoneum
Cytokine | Effect |
---|---|
TGF-β | Stimulates tumor cell attachment and invasion by upregulating plasminogen activator inhibitor type 1 |
Deregulates expression of the major histocompatibility complex | |
Deregulates costimulatory antigen expression by dendritic cells | |
Suppresses Th1-Th2 cells and the conversion of pro-cytotoxic T lymphocytes to cytotoxic T lymphocytes | |
Suppresses the proliferation response to antigen-presenting cells | |
Inhibits natural killer and MA activation | |
IL-6 | Upregulates tumor cell attachment |
Interferes with macrophage maturation in dendritic cells | |
Inhibits cell proliferation through PI3K (phosphatidylinositol3-kinase) | |
Suppresses Th1-Th2 transformation | |
IL-10 | Deregulates expression of major compatibility complex on T cells |
Deregulates costimulatory antigen expression | |
Suppresses cytotoxic T lymphocyte activation and Th1-Th2 transformation | |
Inhibits interferon production | |
Inhibits T cell production | |
VEGF | Increases neoangiogenesis, invasion, and metastasis |
Increases prevalence of ascites | |
FGF-2 | Increases tumor cell invasion and metastasis |
TNF-α | Increases adhesion molecule expression |
Induces tumor cell apoptosis | |
Increases tissue factor expression | |
Decreases the expression of thrombomodulin and EPCR |
Chemokine | Receptor | Cells targeted | Comments |
---|---|---|---|
CCL22 | CCR4 | CD25+CD4+ regulatory T cells | Forster tumor immune escape |
CCL2 | CCR2 | Activated T cells, monocytes, and DC | Deregulate CD8+ T cells and CD68+ macrophage |
CCL3 | CCR2 | Activated T, NK, MO, Eosinophils | Inflammatory cells migration |
CCL4 | CCR5 | DC, MO, NK | Inflammatory cells migration |
CCL5 | CCR2 | Activated T, NK, MO, Eosinophils | Inflammatory cells migration |
CCL7 | CCR2 | Activated T, NK, MO, Eosinophils | Inflammatory cells migration |
CCL18 | Unknown | MOs/MAs | MA produced but not induced in EOC |
CXCL8 | CXCR1, CXCR2 | Neutrophils and resting T cells | Angiogenesis, metastasis |
CXCL12 | CXCR4 | Neutrophils, resting T cells, activated T and B cells, and macrophages | CXCR4 is preferentially expressed on EOC cells |
Product | Procoagulant effect |
---|---|
Leukocytes or MAs | Activate platelets Induce microvascular occlusion Release neutrophil elastase Induce thrombomodulin release from the endothelium Inactivate antithrombin |
Complements | Increase procoagulant factors production Provide membrane surfaces Augment TF expression |
Inflammatory Cytokines | Increase TF production Decrease thrombin, EPCR, and protein S levels Increase C-reactive protein production Increase complement activation Increase platelet count and reactivity |
Chemokines | Activate platelet aggregation and adhesion Attract more leukocytes |